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Abstract
PHARMACEUTICAL PERFORMANCE TESTING OF
COMMERCIALLY AVAILABLE CALCIUM SUPPLEMENTS
Jianqing Liu

The use of dietary supplements is increasing rapidly. More and more people take
one or more types of supplements as a health booster, hoping to satisfy their body’s
daily nutritional need or even relieve disease. Although most dietary supplement
products are used with such health benefit intention, they are still regulated as food,
meaning that their assessed quality and effectiveness are not required by law.
Therefore, the knowledge of the factors that influence the safety and efficacy of these
products has not kept pace with public demand.
Calcium is one of the most widely used supplements, with a confirmed benefit
for bone growth and a variety of diseases such as osteoporosis. Its active ingredients
are usually different types of calcium salts. The products include traditional and quick
dissolving tablets. Early studies showed that the solubility of calcium salt is so low
that its bioavailability and effectiveness in health benefit are questioned due to its
limited dissolution in vitro. With this concern, the pharmaceutical performance of
some commercially available calcium products was tested.
In our research, the quality of a number of calcium supplements was evaluated
by their physical properties, disintegration and dissolution profiles. Physical tests
confirmed the good uniformity of the products. In the USP required dissolution test,
most of those products cannot reach acceptable drug release in the specified time
period. While formulation factors and the salt form of calcium supplements can to
some extent affect their dissolution pattern, it was ultimately considered that the
failure may be related to the poor solubility of the calcium salts.

Based on the results and the proposed mechanisms in the failure in dissolution, a
number of revised dissolution test methodologies were performed differing from the
USP in attempts to increase the active ingredient’s solubility and improvement of the
dissolution test sensitivity. A revised testing criterion was obtained by changing the
parameters of agitation, dissolution volume, and dissolution medium. The optimized
test enhanced the release percentage of calcium and could discriminate the quality of
products. This test was then used to evaluate some quick-dissolving calcium products.
The results confirmed the test’s improvement in discrimination.
In conclusion, the sensitivity of the current USP standard dissolution test is
limited in evaluating less soluble drug release. A revised test method which enhances
the dissolution can serve to better examine and characterize the quality of calcium
supplements.
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Chapter I
Background and Rationale
I.

Calcium
Calcium is one of the most abundant minerals in the human body, contributing

1.5% of the total body weight.1 Of all calcium in the body, over 99% is stored in the
bones and teeth to support their structures. The remaining 1% is found in blood or
intercellular fluid, providing other essential functions in nerve conduction,2,3,4 muscle
contraction,5,6,7 secretion of hormones and enzymes,8,9,10,11 and blood clotting.12,13,14
Without sufficient calcium, a number of related physiological processes will be
affected. Furthermore, when there is not sufficient calcium in the blood, calcium
stored in the bone will be released to maintain blood calcium levels. This calcium
transfer will, in the long run, deteriorate the bone structure, known as osteopenia and
osteoporosis.15,16 Therefore, it is important to consume sufficient calcium to maintain
bone health and other vital body processes as well.

 Calcium’s role in disease prevention and health
Since calcium is involved in many physical reactions and processes, the lack of
sufficient calcium can lead to various diseases or health problems. It is now a most
widely used dietary supplement for many health concerns.
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a. Osteoporosis and osteopenia
Bones change throughout life. During childhood and adolescence, bones increase
in size and mass. About the age of 30, bone mass reaches its peak.17 Regular weight
bearing exercise can contribute to bone strength and density to help prevent
osteoporosis.18
Osteoporosis means “porous bone”.16, 17, 19 Osteoporosis and osteopenia are a
condition in which the normal amount of bone mass has decreased. The bone mass is
determined by bone mineral density (BMD) tests, which measure the BMD in
different parts of the body, hip, wrist, spine, etc. and compare this with an optimal
BMD value of a 30 year old healthy adult. Osteopenia is when the so-called T-score is
between -1.0 and -2.5. When below -2.5, osteoporosis is diagnosed.20, 21 People with
osteoporosis usually have brittle bones, which increases the risk of bone fracture,
particularly in the hip, spine, and wrist. 22
Osteoporosis and osteopenia can result from dietary factors such as:
y chronically low calcium intake in diet
The insufficient calcium intake limits the formation of blood cells and other
essential physiological functions. Bone degradation will then take place to
satisfy the need to maintain plasma calcium levels.18
y low vitamin D intake
Research has proved that Vitamin D can mediate the intestinal absorption of
calcium.23, 24, 25, 26 Sufficient sunshine can induce Vitamin D formation in the
body and thus, increase the calcium absorption. Vitamin D intake from dietary
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supplements has the same effect.
y poor calcium absorption
Besides the lack of vitamin D, other factors that can limit calcium absorption are:
a diet high in phytic acid27, a sedentary life28, and phosphoric acid, as found in
soft drinks29.
y excess calcium excretion
Excessive calcium excretion can be found in patients with celiac desease.30, 31 It
is also reported that increased sodium intake can result in increased calcium
excretion32,33, 34
There are a number of confirmed factors that increase the risk for osteoporosis.
Some of the risk factors cannot be changed, including being female35,
postmenopausal36, 37, having a small skeleton38, being Caucasian/Asian39, 40, family
history of osteoporosis and fractures41, 42, and advanced age43, 44, while many other
factors are controllable, such as calcium-consuming medications like steroids (used to
treat asthma and arthritis)45 and high dosages of thyroid hormone46, inadequate or
excessive intake of fiber and phosphorous nutrients47, excessive exercise48, low body
weight48, cigarette smoking49, 50 and high alcohol consumption51.
Osteoporosis affects people of different races, genders and ethnicities. It is a
serious public health problem for more than 10 million Americans. Women are at
higher risk and it is estimated that they make up 80% of all osteoporosis patients.52
This public concern led to a special authorization from the FDA in 1993,
permitting a health claim for food labels in calcium, saying “adequate calcium intake
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throughout life is linked to reduced risk of osteoporosis through the mechanism of
optimizing peak bone mass during adolescence and early adulthood and decreasing
bone loss later in life”.53 This regulation recognized the evidence that insufficient
calcium intake can lead to low peak bone mass and is considered a risk factor for
osteoporosis.

b. Kidney stones
Kidney stone disease constitutes a major health care burden for the United States
population, causing significant pain, morbidity, and hospitalization.54 Recent reports
suggest that the incidence of these cases is increasing. Men tend to be affected more
frequently than women. Kidney stones are crystallized deposits of calcium and other
minerals in the urinary tract. Calcium oxalate is the most common form.54
Although calcium oxalate stone disease is a very common health problem among
adults in the United States, it is poorly understood at the basic science level. The
disease may be caused by many factors.55,
researched.

55, 56

56

A dietary cause was intensively

Patients have been advised to consume low calcium diets to prevent

kidney stone formation; however, scientists found later that meeting recommended
calcium intake actually reduces the risk.57,

58

It is thus important for patients to

consume appropriate amount of calcium, avoiding deficient or excessive intake.59

c. Phosphorus binding
Hyperphosphataemia plays a key role in the pathogenesis of renal
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osteodystrophy (generalized changes in the bone that resemble osteomalacia and
rickets; occurring in those with chronic renal failure), and phosphate-binding agents
are required in many chronic dialysis patients.60 Calcium acetate is used as a potent
phosphate binder to increase gastrointestinal excretion of phosphorus. Research shows
it increases fecal excretion of phosphorus by binding both dietary and endogenous
phosphorus. Calcium acetate has now taken the place of once commonly used calcium
carbonate and become a common treatment.61, 62 For the most efficient phosphorus
binding, calcium dosing with meals is recommended.61

d. Acid reflux
The full name for acid reflux is gastro-oesophageal reflux, which may be caused
by heartburn or indigestion. Acid reflux usually occurs after eating a heavy meal,
during pregnancy, or as a side effect of constipation.63,64 People who are overweight,
smokers and heavy drinkers have a higher risk of developing the condition. Acid
reflux can also be a symptom of a hiatal hernia.64
A most common antacid used is calcium carbonate, which can also be used as a
combined formulation with other salts (Calcium Carbonate and Magnesia; Calcium
Carbonate, Magnesia, and Simethicone; Calcium and Magnesium Carbonate). Locally,
these salts can neutralize excessive acid in the GI tract and thus effectively alleviate
symptoms. In the stomach, the carbonate can neutralize the excessive acid and thus
relieve the reflux symptom. Some antacids also contain ingredients such as alginates
that relieve the symptoms of trapped gas.65, 66
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e. Hypertension
For a long time, research has indicated that a vegetarian diet high in minerals
(calcium, magnesium and potassium) and fiber and low in fat, can reduce blood
pressure.67
In 1997, the National Heart, Lung and Blood Institute of NIH reported their
findings in “Dietary Approaches to Stop Hypertension (DASH)”. The pattern of
increased calcium, decreased blood pressure was confirmed. And a DASH diet of
sufficient fruits and vegetables as well as calcium from low fat dairy products was
suggested.70
In 2003, a large scale survey (17,030 participants 20 years or older) confirmed
the effect of calcium in lowering blood pressure, and suggested that “If the calcium
intake of the general population were to increase to above 1200 mg, the incidence of
isolated systolic hypertension in the elderly might be decreased.”69
The mechanism is still in debate, but this connection has now been proved.70

f. Cancer
The relationship between calcium intake and the risk of colorectal cancer and
prostate cancer has been reported. Some observational studies suggest that increased
intake of dietary and supplemental calcium is associated with a decrease risk of
colorectal cancer.71, 72, 73 Some other published results, however, indicate that such a
connection is not clear, both in colorectal cancer74, 75, 76 and colon cancer75, 77.
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g. Weight management
It is reported that calcium, especially that from dairy products, can help regulate
body fat.78, 79 For body weight control, low fat dairy products are more beneficial than
calcium supplements alone.80
A summary of the proven and suggested health benefits of calcium
supplementation in the diet is shown below.
Rating

Health Concerns

Gestational hypertension
Lactose intolerance (for preventing deficiency if dairy
products are avoided only)
Osteoporosis
Preeclampsia (for deficiency)
Premenstrual syndrome
Rickets
Celiac disease (for deficiency only)
High blood pressure
High cholesterol
High triglycerides
Amenorrhea (calcium for preventing bone loss)
Colon cancer (reduces risk)
Depression
Dysmenorrhea (painful menstruation)
Gingivitis (periodontal disease)
Insulin resistance syndrome (Syndrome X)
Kidney stones
Migraine headaches
Multiple sclerosis
Pregnancy and postpartum support
Reliable and relatively consistent scientific data showing a substantial health benefit.
Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal
health benefit.
For an herb, supported by traditional use but minimal or no scientific evidence. For a
supplement, little scientific support and/or minimal health benefit.

Table 1. Physiological function of calcium81
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 Recommended intake
The Institute of Medicine (IOM) of the National Academy of Sciences provides
the recommendations for calcium in its Dietary Reference Intakes (DRIs). The
Recommended Daily Amount (RDA) recommends the average daily intake that is
sufficient to meet the nutrient requirements of nearly all (97-98%) healthy individuals
in each age and gender group. Table 2 shows the current recommendations for
calcium for infants, children and adults.
Male and Female Age Calcium (mg/day) Pregnancy & Lactation
0 to 6 months

210

N/A

7 to 12 months

270

N/A

1 to 3 years

500

N/A

4 to 8 years

800

N/A

9 to 13 years

1300

N/A

14 to 18 years

1300

1300

19 to 50 years

1000

1000

51+ years

1200

N/A

Table 2. Recommended Adequate Intake by the IOM for calcium82
The National Institute of Health Consensus Conference and the National
Osteoporosis Foundation support a higher calcium intake of 1,500 milligrams per day
for postmenopausal women not taking estrogen and adults 65 years or older.
It is reported by the Continuing Survey of Food Intakes of Individuals (CSFII
1994-96) that the following percentage of Americans are not meeting their
recommended calcium intake.
44% boys and 58% girls ages 6-11
64% boys and 87% girls ages 12-19
55% men and 78% of women ages 20+ 83
8

 Sources of calcium
In the typical American diet, the major contributors of calcium are milk, yogurt
and cheese.84 Insufficient intake of these dairy foods leads to a possible deficiency in
calcium. The U.S. Department of Agriculture's Food Guide Pyramid recommends that
individuals two years and older eat 2-3 servings of dairy products per day.85 A serving
is equal to: (as shown in Figure 1)
1 cup (8 fl oz) of milk
8 oz of yogurt
1.5 oz of natural cheese (such as Cheddar)
2.0 oz of processed cheese (such as American)

Figure 1. Dietary sources of calcium86
It is recommended that obtaining calcium from the diet is more beneficial than
from supplements, because of its advantage of providing other nutrients that are
important for absorbing and using calcium in the body, such as lactose in milk. The
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2005 Dietary Guidelines for Americans states, "Different foods contain different
nutrients and other healthful substances. No single food can supply all the nutrients in
the amounts you need".87 Building a healthful diet is thus necessary to ensure
sufficient intake.

 Absorption and excretion
The absorption of calcium from the GI tract can be affected by various factors:
y Vitamin D
Vitamin D is a steroid hormone involved in mineral metabolism and bone growth.
It has been widely researched and proved to stimulate intestinal absorption of calcium.
In the absence of vitamin D, dietary calcium is not absorbed efficiently.88, 89, 90, 91
Vitamin D facilitates the expression of a number of proteins involved in transporting
calcium from the lumen of the intestine, across the epithelial cells and into blood.92, 93
Vitamin D can be synthesized by the body when exposed to sunlight and/or obtained
from food or supplements.94
y Pregnancy
It is proved that women in late pregnancy have an increased ability to absorb
calcium from the intestine.95,

96, 97

Animal experiments showed the connection

between this increase and the fetal skeleton formation and mineralization.98
y Food interaction
Vegetables such as spinach, collard greens, sweet potatoes, rhubarb, and beans
contain oxalic acid. Whole grain bread, beans, seeds, nuts, grains, and soy isolates
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contain phytic acid. Both can bind to calcium and prevent it from being absorbed.99
y Age
For infants and young children when bones are growing, calcium absorption can
reach 60% to satisfy the need of bone growth. The calcium absorption of a healthy
adult is around 15-20%. When people get even older, the calcium absorption
decreases even more.100
There are also a few factors affecting calcium excretion:
y Sodium and protein
It is reported that increased intake of dietary sodium and protein can increase
calcium excretion.101, 102
y Potassium
Intake of potassium can help decrease calcium excretion, especially for post
menopausal women.103, 104
In conclusion, a number of factors can have effects on the absorption and/or
excretion of calcium. The deficiency of calcium is not uncommon among people.

II.

Dietary Supplements

 Definition of nutraceuticals, dietary supplements
In 1989, Stephen DeFelice, MD, founder of the Foundation for Innovation in
Medicine (FIM) first combined the word “nutrition” and “pharmaceutical” and
invented the term “nutraceutical”.105 After that, this word has been commonly used in
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our daily life without a strict regulatory definition.106 In DeFelice’s words,
nutraceutical is “a food (or part of a food) that provides medical or health benefits,
including the prevention and /or treatment of a disease”. Such definition is so broad
that it obviously includes nutrition strengthened food and many of our daily foods.
Dr. Ekta K. Kalra suggested in 2003 that food which “is being cooked or
prepared using ‘scientific intelligence’ with or without knowledge of how or why it is
being used” should be categorized into “functional food”, so that these can be
separated from more drug-like nutritional products. Kalra proposed that
“nutraceutical”:
y must not only supplement the diet but should also aid in the prevention
and/or treatment of disease and/or disorder.
y are represented for use as a conventional food or as the sole item of a meal or
diet.107
If Kalra’s proposal is accepted, the term “nutraceutical” will have a much narrower
meaning than it currently has. Nowadays, nutraceutical is widely used like a synonym
of “dietary supplement”.
But till now, the term “nutraceutical” has still not been accepted officially. The
Dietary Supplement Health and Education Act (DSHEA) and United States
Pharmacopoeia (USP) use “dietary supplement” (DS) to regulate related products.
According to the definition by the DSHEA in 1994, a dietary supplement:
y is a product that is intended to supplement the diet and that bears or contains
one or more of the following dietary ingredients: a vitamin, a mineral, an herb or
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other botanical, an amino acid, a dietary substance for use by man to supplement
the diet by increasing the total daily intake, or a concentrate, metabolite,
constituent, extract, or combinations of these ingredients.
y is intended for ingestion in pill, capsule, tablet, or liquid form.
y is not represented for use as a conventional food or as the sole item of a meal
or diet.
y is labeled as a "dietary supplement."
y includes products such as an approved new drug, certified antibiotic, or
licensed biologic that was marketed as a dietary supplement or food before
approval, certification, or license (unless the Secretary of Health and Human
Services waives this provision).108
Here, the “dietary ingredient” may include vitamins, minerals, herbs or other
botanicals, amino acids and substances like enzymes, organ tissues, glandulars, and
metabolites. DS can be extracts or concentrates, in forms like tablets, capsules,
softgels, gelcaps, liquids or powders.
Therefore, the calcium supplements studied in this research fall into this “dietary
supplement” category and must comply with all requirements of the regulation.

 The use of dietary supplements
By their dietary function or origin, DS are grouped into three major categories: 1)
substances with proved nutritional function (vitamins, minerals, amino acids and fatty
acids); 2) botanical products and their concentrates or extracts (garlic, ginseng and St.
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John’s Wort); and 3) other substances with physiologic roles (pyruvate, steroid
hormone precursors and chondroitin sulfate).109
Many people in the western countries view DS as an important component of a
healthy lifestyle. They take DS for a variety of reasons. Most important motivations
include ensuring nutritional adequacy, maintaining tissue structures and functions,
reducing the risk of diseases, improving physical performance and withstanding
aging.110, 111 The rapid growth in the DS market reflects consumers’ eager need and
desire for health benefits. The scientific evidence to support the DS’s efficacy,
however, varies greatly from one product to another. Some active ingredients like
vitamins and calcium are extensively researched, while the effects of some others,
especially natural products, are in continuous debate due to the lack of their
experimental proof of safety, effect, and efficacy.110

 The regulation of dietary supplements
The two major government agencies that regulate DS products are the Food and
Drug Administration (FDA)113 and the United States Pharmacopoeia (USP). The FDA
regulates DS through its subsidiary organization, the Center for Food Safety and
Applied Nutrition. Before October in 1994, DS were treated by the same regulatory
system as other traditional foods, under the Food Drug and Cosmetic Act (FDCC Act
- FDCA).114 After President Clinton signed DSHEA as an amendment to FDCA, this
new law became the framework to regulate DS.115
Basically, DS are still regulated as foods under DSHEA. Manufacturers only
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need to ensure the safety of their product. There is no need to present evidence to
substantiate the effectiveness of the DS, unlike drugs and food additives.116 Under this
law, “DS manufacturers do not have to register with the FDA, or obtain FDA approval
before producing or selling their products. Prior to marketing a product,
manufacturers are responsible for ensuring that a dietary supplement (or a new
ingredient) is safe before it is marketed. FDA has the authority to take action against
unsafe dietary supplement products. Manufacturers must ensure that their product
label information is truthful and not misleading.”115
As for the safety inspection, the manufacturers are not legally required to report
related “adverse effect” reports to the FDA. And the FDA is not capable of analyzing
the composition of every DS product, due to limited resources. The FDA never
reviews or analyzes DS before the supplement goes on the market. The monitor of DS
safety is through voluntary adverse event reporting, labeling claims, literature, and
routinely random laboratory testing, etc. The manufacturers are also responsible for
ensuring that the “Supplement Fact” label and ingredient list and content are
accurate.116
Since DS are regulated as foods, it is illegal to promote them on their labels as a
treatment, prevention or cure for a specific disease or condition.116, 117 By law, only
three types of claims can be used for DS: health claims that describe the link between
a substance and disease or a health condition; structure/function claims which refer
to the intended benefits; nutrient content claims that specify the amount of the
dietary substance in the product.118, 119 When a structure/function claim is presented, a
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“disclaimer” must also be marked on the labeling that says: “This statement has not
been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or
prevent any disease.”119 Any violation will lead to the loss of the product’s status as a
DS and be thus considered an unapproved or misbranded drug.
Over the years, with the increasing popularity of DS, but also based on the need
to ensure the effectiveness of DS, the USP-NF has added a series of supplemental
chapters and related monographs to test vitamin and mineral and some botanical
products. In General Chapters, a chart for evaluating dietary supplement products has
also been developed as a standard guidance.
It is voluntary for manufacturers to follow the standards prescribed in USP. In the
Dietary Supplement Verification Program (DSVP), the manufacturers can apply for
the tests by USP and obtain an authorization of the DSVP mark which assures
consumers, health care professionals, and supplement retailers that a product:
y Contains the ingredients stated on the label in the declared amount and
strength
y Meets specified standards for product purity by meeting requirements for
known contaminants
y Has been manufactured properly by complying with USP and proposed FDA
standards for good manufacturing practices (GMPs)120
At present, USP focuses on developing testing method to decide the products’
acceptability, stability and performance in approved applications, while the FDA
places more emphasis on marketing, labeling and safety issues.121 In addition to USP,
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the Center for Food Safety and Nutrition of the FDA also regulates vitamins, minerals
and other DS.122 The advertising of DS is in the charge of the Federal Trade
Commission (FTC). 117, 118

 Concise history of dietary supplement regulation
Although the USP and the FDA share a common mission of actively promoting
the public health, and USP’s DSVP complements FDA’s regulation of DS products,
the two agencies, however, are separate programs and focus on different aspects of
DS regulation.
A brief history of developments of DS’s regulation is shown in the following
table.
1938

The Federal Food, Drug and Cosmetic Act acknowledges vitamin,
mineral and other dietary properties of foods. The FDA uses the drug
provisions of the law to stake its claim to reclassify dietary supplements
as drugs based on their label claims.

1941

The first recommended daily allowances (RDAs) are published
establishing the basis for the FDA’s regulation of vitamins and minerals,
despite opposing opinions claiming the RDA was not reflective of
current scientific advances on the benefits of nutrients in maintaining
health

1966-73

The FDA publishes proposed new guidelines for labeling and content of
dietary supplements; however, public opposition forces further hearings.
Finally in 1973, the FDA publishes final regulations classifying any
supplements stronger than 150 percent of the RDA as drugs.

1976

Proxmire Bill was passed in congress, prohibiting the FDA from
regulating vitamins and minerals as prescription drugs.
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1990

Nutrition Labeling and Education Act (NLEA) was signed by President
Bush. The FDA was authorized to implement this law.

1991

USP holds an open conference on vitamins, minerals, and nutritional
supplements. The first proposals are discussed and reviewed.

1992

The Health Freedom Act was passed to protect the Americans to choose
safe and effective dietary supplements.

1993

Supplement 8 to USP XXII: The first standards are established, including
requirements for initial disintegration testing and for dissolution testing
if disintegration attempts fail. USP Pharmacopeial Forum publishes a
proposal for establishing dissolution requirements for nutritional
supplements

1994

US Congress passes DSHEA. Dietary supplements are regulated by the
FDA in this new framework.

1995

Supplement 1 to USP 23: Dissolution testing is established as a
requirement for nutritional supplements, including folic acid, index
vitamins, and index elements.

1995-1998 Subsequent USP 23 Supplements: fine-tuning of requirements, test
methods, and assays.
1998

Inclusion of botanicals in USP/NF monographs.

1999

The FDA requires that a “Supplement Facts” panel appear on dietary
supplement labels.

2004

The final regulation of GMP for dietary supplements was issued

Table 3. A summary of the development of dietary supplements’ regulations.123, 124

 The bioavailability of dietary supplements
All the aforementioned regulations aim to ensure the safety and efficacy of DS.
However, since DS are still by far regulated as foods, the regulatory framework for
them is not as rigorous as it is for drugs. Therefore, information about bioavailability,
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an essential factor that influences both the safety and efficacy of the product, has not
yet been a mandatory specification. The lack of knowledge in bioavailability has
limited

physicians

or

other

health

professionals

from

giving

rigorous

recommendations and advice to the public. Thus, a careful choice must be based on
cost and effectiveness. For instance, the cost of a 30-day supply of a calcium
supplements varies from $2 for calcium carbonate and $5 for calcium lactate to over
$10 for calcium gluconate. And calcium carbonate is generally considered to be the
most bioavailable source.
The increasing use of the DS products has raised many concerns on the need to
use bioavailability as an indicator for the products’ effectiveness. Developing a way to
solve this issue is necessary and urgent, but challenging as well.
First, scientists have not reached a consensus on how to define bioavailability for
DS. A most simple definition is the proportion of a nutrient or bioactive ingredient
(relative to its total amount in the DS) that is absorbed from the gastrointestinal tract,
which is a straightforward derivation from the concept of drug bioavailability.125
A challenging aspect to this is that many DS are used in different therapeutic or
nutritional support purposes. While most individuals may consume calcium
supplements to satisfy their required daily standard intake (RDA), the same calcium
product may also be used to reduce acid or strengthen bones. Other DS, like vitamins
or natural products, are also used for effects other than adequate nutrition. Effects like
lipid lowering, memory enhancement and sleep improvement are frequently
advertised. Such intake purposes are for more pharmacological rather than nutritional
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effects.
Second, many bioactive ingredients in supplements are also endogenous
substances (vitamins, minerals, amino acids), which are subject to physiological
controls of the active in the DS. Therefore, these ingredients’ plasma concentration
fails to characterize the product’s bioavailability. For example, our bodies need to
maintain a rather steady calcium level in the blood. Even when the amount of calcium
in the body has raised after the intake of calcium supplements, the plasma
concentration remains little changed. Thus, the traditional methods in drug availability
evaluation will face unique difficulties when dealing with these products.
Third, the bioavailability performance of many DS is not extensively researched.
Sources quote that the bioavailability of folate from food is only half that of folic acid
from supplements, but no sufficient data are available to support and compare this
claim. These data are necessary to set dietary standards like Dietary Reference Values
(DRVs) and Recommended Daily Amounts (RDAs). And the customization of
product use by special groups such as the elderly or pregnant women, can only be
achieved by collecting sufficient related data.
Facing so many challenges, the USP has developed disintegration and dissolution
standards for vitamins and minerals as an in vitro indicator for bioavailability.
Although the solubility of a substance alone cannot determine bioavailability, the
dissolution test is a “good step forward” as stated by Dr. V. Scrini Srinivasan.125 The
test is based on evaluating the dissolution of the DS’s index vitamin and/or mineral,
which in part are selected based on their limited solubility.
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 The dissolution tests for dietary supplements
Over recent years, the USP has established specifications for a number of DS.
The tests for vitamins, minerals, and some natural products – botanicals have been
standardized.
The following table lists the dissolution requirements and references for the six
USP classes of vitamins, minerals and vitamins with minerals.

Class

Dissolution

Reference

I. Oil-soluble vitamins

Not required

II. Water-soluble vitamins

One index vitamin;

126

Tablet and capsule assays

Folic acid if present
126

III. Water-soluble

One index vitamin and one index

Tablet assays

vitamins with minerals

element;

Capsule assays

127

Folic acid if present
126

IV. Oil- and water-

One index water-soluble vitamin;

soluble vitamins

folic acid if present

V. Oil- and water-soluble

One index water-soluble vitamin and

Tablet assays

vitamins with minerals

on index element; folic acid if present

Capsule assays

VI. Minerals

One index element

Tablet and capsule assays

Tablet and capsule assays

128
126
126

Table 4. Dissolution requirement for dietary supplements.
However, it should be noted that the dissolution test which is significantly
affected by solubility of the active substance, may not always be an appropriate
measure of bioavailability. There are other factors like absorption and formulation
also affecting the bioavailability in a great deal.
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III. Calcium supplements
 Types of calcium products and expected performance for product efficacy
There are many types of calcium supplements on the market, both single entity
and in combination with other vitamins and minerals. The majority are in traditional
solid dosage forms, while some chewable tablets also become popular for their
convenience.
Calcium in traditional tablets often is taken to be absorbed for systemic effects.
Both disintegration and dissolution tests are required to guarantee its efficacy. As for
chewable tablets, some are intended to have local effects, as an antacid in stomach. In
that case, no dissolution test is necessary. For tablets labeled for any indication other
than, or in addition to, antacid use, they must satisfy the specification in their
monographs.129
The most popular calcium salt forms are carbonate (Tums, OsCal, etc) and citrate
(NatureMade, Citracal). Calcium carbonate is most widely used because it is
inexpensive and provides the most calcium per tablet. One disadvantage is that
carbonate can cause bothersome stomach gas. Since its solubility is rather low, extra
stomach acid can help its dissolution and absorption. It is therefore advised to be
taken with a meal.
The absorption of calcium citrate is higher than calcium carbonate; therefore it
does not require to be taken with meals. For those with decreased stomach acid, the
absorption of calcium citrate is far better than of carbonate. A number of studies have
shown the absorption of calcium citrate is only moderately higher than
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carbonate.129-134
Some new salt forms of calcium supplements have also been compared with
carbonate and citrate. In a recent study, calcium formate showed a significantly better
absorption. There are also other salt forms available on the market: tricalcium
phosphate (Posture), calcium citrate malate (Calcimate), calcium lactate and calcium
gluconate. Some calcium supplements also contain vitamin D, which facilitates the
calcium absorption.
For these products, the amount of elemental calcium is the indicator of their
effective calcium content, which is defined as “the amount of calcium in a calcium
supplement”.129 During digestion, the elemental calcium is released from the
compound (carbonate, citrate, etc.) and becomes available for absorption. For
example, calcium carbonate is 40 percent calcium (1250 mg calcium carbonate yields
500 mg elemental calcium); calcium citrate is 21 percent calcium (600 mg calcium
citrate provides 122 mg elemental calcium). Most products use the total number
instead of the percentage as part of their brand name, indicating the amount of
elemental calcium in each tablet, i.e., Caltrate 600, OsCal 500, etc. The following
table and figure compare the elemental calcium in different products.
Salt
Carbonate
Phosphate
Citrate
Lactate
Gluconate

Molecule
CaCO3
Ca3(PO4)2 + CaNaPO4
C12H10Ca3O14·4H2O
C6H10CaO6
C12H22CaO14

Molecular Weight
100.09
310.18
570.49
218.22
430.37

Elemental Calcium percentage
40%
38%
21%
13%
3%

Table 5. The comparison of elemental calcium of different calcium salts.169

Some products have very low calcium content; it is therefore necessary to take
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more tablets to satisfy daily need.
There are also some naturally occurring calcium carbonate products available,
including dolomite, oyster shell, bone meal, and coral calcium. However, to this point
in time, there is no regulatory agency testing these supplements. It is up to the
manufacturer to assure that the lead content meets the FDA requirements.
The amount of elemental calcium in a tablet determines the amount absorbed
from different calcium products. Exceeding 2,500mg of elemental calcium per day
can result in toxicity.

 Current USP requirements for calcium supplements
The performance test of dietary supplement products includes: <1216> Tablet
Friability, <2040> Disintegration and Dissolution of Dietary Supplements,
<2091>Weight Variation of Dietary Supplements and <2750> Manufacturing
Practices for Dietary Supplements.135 Since there are no specified friability,
disintegration and manufacturing practice tests in the monograph of any calcium
product, these tests follow the same guideline as with other solid dosage DS
formulations. The disintegration test is therefore performed in distilled water, unlike
the following dissolution test.
Since calcium products usually have limited solubility, which significantly affect
their absorption and bioavailability, dissolution is an important factor. Different
calcium salts may exhibit different dissolution profiles. USP therefore requires
different specification for each product.
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Existing requirements:
y Calcium acetate tablet 136
Medium: water; 900mL
Apparatus 2: 50 rpm
Time: 30 minutes
Procedure: atomic absorption spectrophotometry
Tolerances: not less than 80% (Q) of the labeled amount of C4H6CaO4 is
dissolved in 30 minutes.
y Calcium carbonate tablet 137
For Tablets labeled for any indication other than, or in addition to, antacid use.
Medium: 0.1N hydrochloric acid; 900mL
Apparatus 2: 75 rpm
Time: 30 minutes
Procedure: atomic absorption spectrophotometry
Tolerance: not less than 75% (Q) of the labeled amount of CaCO3 is dissolved in
30 minutes.
y Calcium gluconate tablet 138
Medium: water; 900mL
Apparatus 2: 50 rpm
Time: 45 minutes
Procedure: atomic absorption spectrophotometry
Tolerance: not less than 75% (Q) of the labeled amount of C12H22CaO14 is
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dissolved in 45 minutes.
y Calcium lactate tablet 139
Medium: water; 500mL
Apparatus 1: 10 rpm
Time: 45 minutes
Procedure: pooled sample assay <711>
Tolerance: not less than 75% (Q) of the labeled amount of (C6H10CaO6·5H2O) is
dissolved in 45 minutes.
y Calcium pantothenate tablet 140
Medium: water; 900mL
Apparatus 2: 50 rpm
Time: 45 minutes
Procedure: infrared absorption
Tolerance: not less than 75% (Q) of the labeled amount of C18H32CaN2O10 is
dissolved in 45 minutes.
y Dibasic calcium phosphate tablet 141
Medium: 0.1N hydrochloric acid; 900mL
Apparatus 2: 75 rpm
Time: 45 minutes
Procedure: atomic absorption spectrophotometry
Tolerance: not less than 75% (Q) of the labeled amount of CaHPO4·2H2O is
dissolved in 45 minutes.
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All selected above are calcium supplements in solid dosage formulation with
systemic absorption. For products used as an antacid, including some calcium
carbonate tablets136, calcium carbonate and magnesia tablets142, calcium carbonate,
magnesia and simethicone tablets143, and calcium and magnesium carbonate tablets144,
there are no dissolution requirements for these products. They are subject to an
acid-neutralizing capacity test <301> to confirm their claimed efficacy.
Specifications that do not exist:
Note that not all calcium supplements have their specifications in USP. Examples
are calcium citrate tablets, supplement with vitamin D and other new salt forms.

 Results of previous studies on calcium supplements
The suggestion to take calcium supplements for health benefit or disease
treatment has been brought up since the 1980s.145, 146 Because a series of clinical and
demographic research confirmed the hypothesized benefit

147-150

, the importance of

calcium supplementation was promoted and now has become a common health
concern around the world. With its increasing popularity, the research focus has
changed from demographic studies, which intend to promote awareness, to
investigations more related to the product quality and efficacy, which helps consumers
and physicians make the better choices in purchasing or advising.
Concerning the active ingredients, it was reported that the combination of
Vitamin D and calcium can lead to much better calcium absorption.151 Early studies
also agreed that extra estrogen intake can also facilitate calcium supplementation152-154,
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and this combined treatment was very common among menopausal women
consumers. However, as more reports confirmed the potential adverse effect of
estrogen leading to heart attacks155, breast cancer156 and strokes157,

158

, the FDA

ordered warnings on all estrogen labels159, and the estrogen replacement therapy is no
longer suggested with calcium supplementation.
In the 1990s, coral calcium became popular with its promotion of “natural
source” and “better absorption”. Such claims were supported by some published
research.160 The marketing of this product raised questions.161-163 Research which
followed proved there was no significant advantage.164-167 In 2003, the FTC and FDA
officially charged marketers of coral calcium supreme dietary supplement with
making false and unsubstantiated claims.168
Since the FDA has limited resources in evaluating the calcium supplement
quality, studies on quality assessment were mostly performed by academic
laboratories and other third-party organizations. Early in 1989, cases of calcium
tablets with impaired disintegration and dissolution were reported.170 Dr. Ralph
Shangraw pointed out that many supplements failed to meet USP standards and
suggested a comprehensive look at the salt type, the condition of the patient and the
time of administration for the best health benefit.171, 172 A more recent investigation of
fifteen popular calcium products showed that two of them failed the disintegration
requirement and exceeded lead amount limits.173 With the emergence of new calcium
salt and new formulations, related studies have also been performed.174, 175 Therefore,
it is necessary to test, characterize, and control the quality of marketed products.
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Chapter II

Goals and Objectives

 General goal
Given the history just presented (Chapter I), concerning pharmaceutical efficacy
issues related to nutraceuticals, the primary goal of this research goal was to evaluate
both the pharmaceutical quality of several commercially available calcium
supplements, as well as the appropriate revisions of the USP methodologies (esp.
dissolution) for testing these products. Physical tests were performed to examine their
dosage uniformity and other physical properties. Disintegration and dissolution were
tested to estimate these tablets’ in vitro behavior as an indicator of these supplements’
in vivo bioavailability and effectiveness.
In order for a drug to have its effect after oral administration, it must go into
solution and then diffuse through the gut wall into the body. The first step in that
process is the disintegration of the dosage form followed by dissolution of the active
ingredient. Dissolution of a pure substance follows the Noyes Whitney Equation:

dm
= k D A(C S − C B )
dt

(Equation 1)

Where dm/dt is the rate of dissolution, kD is the dissolution rate constant, A is the
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surface area of the dissolving solid, CS is the saturation concentration of drug in
diffusion layer and CB is the concentration of drug in dissolution media (or the bulk).
Dissolution rate constant kD is a function of the diffusion coefficient D and the
thickness of the diffusion boundary layer δ .
kD =

D

(Equation 2)

δ

In order to increase dissolution rate of poorly soluble drugs, stirring speed can be
increased to reduce the thickness of the diffusion boundary layer δ . At the same time,
the increased agitation also facilitates the disintegration, breaking the tablet into fine
particles in a shorter period of time and thus increasing the surface area A. Another
approach is to keep a low CB during the course of dissolution. The third is to increase
the solubility of the drug in the medium solution. With greater CS, both the dissolution
rate and extent are enhanced. Based on this dissolution theory, a series of experiments
were performed in an attempt in the second phase of this work to achieve the best
dissolution profile by changing each variable. The testing parameters under which the
dissolution test reaches the best sensitivity are called the “optimized testing criterion”.
This revised testing method (“optimized methodology”) was then used in the test of
several other calcium products to confirm its feasibility and sensitivity.

 Specific Objectives


Evaluate the pharmaceutical properties of several calcium supplements,
including weight variation, thickness, hardness, friability and disintegration.
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Examine the dissolution of the products by USP standard dissolution
method.



Improve the dissolution test method by increasing stirring speed and the
volume of dissolution medium.



Improve the dissolution test method by using phosphate binding medium



Improve the dissolution test method by adding surfactant to the dissolution
medium



Determine optimized dissolution testing conditions



Demonstrate utility and sensitivity of “optimized” methodology by
comparing products’ dissolution under “optimized” vs. USP conditions.
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Chapter III

Materials and methods

To achieve the goal of the research, studies have been carried out in two parts:
the first (Phase I) is to evaluate the pharmaceutical quality of commercially available
calcium supplements; the second (Phase II) is aimed to optimize the sensitivity and
reproducibility of the test guidance (i.e.: performance testing standards); the third
(Phase III) is to evaluate both oral and chewable calcium supplements with the
optimized testing method.

Phase I:
In order to assess the pharmaceutical quality of the calcium products, the
following tests were performed:
I.

Disintegration

II. Hardness
III. Dissolution
Phase II:
To revise the standard test, so as to develop and propose an improved testing
method of dissolution, the studies went as follows, where variables were changed
which in theory, should affect dissolution kinetics and thus improve the test
sensitivity:
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I.

Increase the speed of dissolution medium

II. Increase the volume of dissolution medium
III. Use other buffer system as the dissolution medium
IV. Addition of surfactant
Phase III:
To evaluate chewable calcium products (chewable, slow and fast dissolve, and
oral, three salt forms) with the optimized dissolution testing method. Compare the
revised test with the USP standard test results

Materials and equipments
A list of chemicals, calcium supplement products, equipments and reagents
prepared to carry out the aforementioned tests is shown below.

A. Chemicals:

Chemical

Provider

Hydrochloric Acid (HCl)

Fisher Chemical

Sodium Chloride (NaCl)

Fisher Chemical

Sodium Hydroxide (NaOH)

Fisher Chemical

Potassium Phosphate Monobasic (KH2PO4)

Fisher Chemical

Sodium Lauryl Sulfate (SLS)

Fisher Chemical

Tween 80

Fisher Chemical

Calcium Ionic Strength Adjustor (ISA)

Orion

Calcium Standard (0.1M Ca2+)

Orion

Table 6. Chemicals used in research
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B. Commercial calcium products

Brand name

Salt form

Lot/Exp date

Elemental calcium

CVS

Calcium Carbonate

OMB0304; 06/05

600mg

Caltrate

Calcium Carbonate

483-005; 08/02

600mg

RiteAid HiCal

Calcium Carbonate

OCO1486; 02/05

200mg* carbonate

Major

Calcium Carbonate

2351; 06/05

240mg* carbonate

Walgreens

Calcium Carbonate

OFO1786; 06/05

600mg

Leader

Calcium Carbonate

1HN0579; 04/04

600mg

OsCal

Calcium Carbonate

1G0925; 05/04

500mg

PhosLo

Calcium Acetate

POL336; 12/03

667mg* acetate

NatureMade

Calcium Carbonate

MK11563; 10/05

500mg

NatureMade

Calcium Citrate Vit D NB10929; 02/06

250mg

Tums **

Calcium Carbonate

750mg* carbonate

4D19, 4H08

Table 7. Commercial calcium products tested in the research.
* For PhosLo, 667 mg is the amount of calcium acetate salt in one tablet; for HiCal, Major
and Tums, labeled content is the amount of calcium carbonate salt in one tablet.
** Tums is the chewable supplement in quick-dissolve formulations in the research. All
others are in traditional tablet formulation.

C. Equipments


Disintegration apparatus
Vankel® Model 35-1200, Serial 20-A72-010
Basket-rack assembly and 1000ml low-form beakers are also provided by
Vankel®. (USP apparatus A and B)



Ultrapure water system
Barnstead® NANOpure UV, Model NO. D7334 Serial NO. 852970479018



Balance
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Mettler Toledo® AB54 NO. 228064 SNR 1115352741


pH meter
Fisher Scientific Accumet® Basic AB15 pH Meter



Hardness tester
Vector/Schleuniqer 6D Ver 3.0



mV meter
ThermoOrion® Model 290



Calcium electrode
ThermoOrion® Ionplus®



Dissolution apparatus
Vankel® VK 7000

D. Reagents


Water:
Directly obtained from Nanopure UV Ultrapure water system.
pH value ranges from 5-7.



Simulated gastric fluid (SGF) for disintegration test:
Simulated gastric fluid was prepared according to USP standards. 6 g of NaCl
was placed in a 3 L round bottom volumetric flask, 2500 ml of distilled water
and 21mL of 1N HCl were added and mixed well. The volume was adjusted and
the solution pH was adjusted to 1.5 with either 1N HCl or 0.2N NaOH.
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Simulated intestinal fluid (SIF) for disintegration test:
Simulated intestinal fluid was prepared according to USP standards. 20.4 g of
potassium monobasic phosphate (KH2PO4) was placed in a 3 L round bottom
volumetric flask, and 570ml of 0.2N NaOH was added. The volume was
adjusted with distilled water. The solution pH was adjusted to 7.5 with either 1
N HCl or 0.2 N NaOH.



Simulated gastric fluid for dissolution test
1. Dissolve 50mL HCl in 6L distilled water
2. Stir well and adjust pH to 1.0 with either 1 N HCl or water.



Phosphate buffer system
1. Measure out 76.7 g KH2PO4 and 192.3 g K2HPO4.
2. Dissolve the powders in 3 L distilled water.
3. Check the pH and adjust to pH=7.5. Add HCl or NaOH if necessary.

Methods
 Phase I - Testing of performance of commercially available calcium products
As dietary supplements, the performance tests of calcium products include tablet
friability, disintegration and dissolution, and weight variation.1
I.

In vitro disintegration:
According to USP General Chapters <701> DISINTEGRATION, complete
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disintegration is defined as “that state in which any residue of the unit, except
fragments of insoluble coating or capsule shell, remaining on the screen of the test
apparatus is a soft mass having no palpably firm core.” Disintegration “does not imply
complete solution of the unit or even of its active constituent.”3
Standard apparatus includes Apparatus A and Apparatus B. For tablets smaller
than 18mm in length, Apparatus A should be used, while others should be tested in
Apparatus B.2 In our research, five products, namely Caltrate, Walgreens, HiCal,
Leader and OsCal, are longer than 18 mm, and therefore must be tested in Apparatus
B.
The apparatus A consists of a basket-rack holding six open-end glass tubes. Each
is 7.75±0.25 cm long and has an inside diameter of about 21.5 mm and wall thickness
of approximately 2 mm. Attached by screws to the underside of the lower plate
holding the tubes are a 10 mesh stainless steel wire cloth. The basket rack is
suspended through an arm immersed in a 1000 mL beaker containing disintegration
medium at 37±2 °C. The basket rack is never less than 2.5 cm below the surface of
the fluid or above the bottom of the beaker.3 The apparatus B has a similar basket-rack
with three open-end glass tubes, which has an inside diameter of 30 mm.2
For uncoated tablets, the disintegration medium should be 900ml of distilled
water, and disintegration be run for thirty minutes. In order to meet USP
specifications, six tablets should first be tested. If 1 or 2 tablets fail to disintegrate
completely within 30 minutes, the test should be repeated on an additional twelve
tablets. Not less than 16 out of 18 tablets tested should disintegrate completely. For
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those tablets longer than 18 mm, tests are required to be performed in Apparatus B.
Since the goal of the study was to both assess product meeting the USP
specifications as well as characterize product performance, our disintegration test was
performed in three media: simulated gastric fluid (SGF) with a pH 1.5, simulated
intestinal fluid (SIF) with a pH 7.5 and distilled water (DW) from NANOpure water
system with a pH 5-7. The disintegration times for 18 randomly selected tablets from
each product were measured at the same time, if a preliminary study of disintegration
time gave disintegration time greater than 5 minutes; otherwise six tablets were
measured at a time, with individual disintegration time readings taken, and the study
repeated two more times.
In order to obtain the disintegration time of each tablet, our tests were stopped
every 15 seconds to observe the sample. This visual was needed since the
disintegration medium soon became milky in appearance, as more calcium
disintegrated and dissolved. Also, the test was not discontinued at 30 minutes, but
went on until every tablet had disintegrated completely or up to 8 hours, whichever
occurred first. Time was noted for the disintegration time of each tablet, and their time
(n=18) averaged to determine the “average time for disintegration and variability” for
the specific product. These data were then used to determine:
1.

Whether the product passed the USP monograph standard for disintegration.

2.

Exhibited a significantly short or long disintegration time.

3.

Exhibited sensitivity in disintegration to pH conditions.

4.

Showed broad variability in disintegration to pH conditions.
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II. Tablet hardness and thickness
The hardness tester uses two steel moving bars to squeeze the tablet tested. In the
squeezing process, the increasing strength resistance is measured. At the moment the
tablet breaks, the force recorded is then the tablet hardness.
Ten (10) tablets of each product were randomly selected from one batch (the
same bottle). Their hardness was tested by a hardness tester and their thickness was
measured by the callipers attached. The average and variation were calculated.
To study the connection between tablet hardness and disintegration time, three
products (CVS, OsCal and Caltrate) were picked out as representatives for quick,
average and slow disintegrating formulations. Their hardness and disintegration were
compared.

III. Tablet friability
In the friability test, a specially designed drum is used to tumble the tablets. The
drum has an internal diameter between 283 and 291 mm and a depth between 36 and
40 mm. It is made of synthetic polymer with polished internal surfaces. No static
charge should build up during the test. In the test, the drum keeps rolling and
tumbling the tablets inside with each revolution. The collision of tablet onto the drum
wall or between each other may lead to their breakage, cracking or weight loss. If any
tablet breaks in the process, the whole set fails the test. A maximum weight loss of not
more than 1% of the weight of the tablets being tested is considered acceptable.
Chewable tablets are not subject to this test.4
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For each calcium product, ten (10) tablets were randomly selected. Having been
dedusted and accurately weighed out, these were placed in the drum. After the drum
completed 100 rotations, the tablets were removed, dedusted again and weighed out
accurately. Then, the weight loss percentage was calculated.

IV. Weight variation
Weight variation is a method to estimate dosage uniformity.6 In the test, twenty
(20) randomly selected tablets were accurately weighed out individually. The average
and standard deviation were calculated. The USP requirement is met if the weights of
not more than 2 of the tablets differ from the average weight by more than the
percentage listed in the table below, and no tablet differs in weight by more than
double that percentage.
Average weight of tablet, mg
<130
130~324
>324

Percentage difference
10
7.5
5

Table 8. Passing criteria of weight variation test5, 6

The percentage difference used in our research is 5%, since all our calcium
products exceed 324 mg.

V. Dissolution by USP method
In the USP General Chapters, dissolution condition for index minerals is:
Medium: 0.1 N hydrochloric acid; 900 mL.
Apparatus 1: 100 rpm, for capsules.
Apparatus 2: 75 rpm, for tablets.
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Time: 1 hour.2
Since some calcium supplements have their own specified monograph which has
different testing parameters, we followed the conditions for calcium carbonate tablets:
Medium: 0.1 N hydrochloric acid; 900 mL.
Apparatus 2: 75 rpm
Time: 30 min.7
If necessary, the testing time will be as long as two (2) hours for dissolution to
complete or reach saturation. Dissolution was measured using USP General Chapter
<711> apparatus II, paddle stirring element.6 (Apparatus I is the basket stirring
element.)
USP apparatus II consists of a motor, a paddle shaft as the stirring element, and a
covered glass vessel, cylindrical on the bottom that contains the dissolution medium.
The shaft is positioned so that its axis is not more than 2 mm at any point from the
vertical axis of the vessel and rotates smoothly without significant wobble. The
dissolution medium is heated by a water bath to keep the inside temperature at 37±
0.5℃ during the test. The dosage unit should be positioned at the bottom of the
vessel before the start of the test.
To meet the USP specifications, calcium carbonate, 75% (Q) of its label claim,
needs to be released in 0.1N hydrochloric acid in 30 minutes, at a stirring speed of 75
rpm. For calcium acetate tablets, at a stirring speed of 50 rpm, no less than 80% of the
labeled amount should be dissolved in water in 30 minutes. The tablets of other
calcium forms have no specific requirement in USP, and thus were treated the same
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way as calcium acetate and carbonate tablets. Calcium concentration was measured by
a calcium ion selective electrode and an mV meter. Standard calibration curves were
developed for the electrode. From these, the concentration of the drug dissolved was
determined, with percent of drug release calculated to generate product dissolution
profiles.
In our research, six (6) tablets were tested at a time. When the dissolution
medium was preheated 37±0.5℃, tablets were dropped to the bottom of each beaker
and the test was started at the same time. At specific time intervals (usually 10 or 15
min), 2 mL sample solutions was drawn out, and filtered into a test tube. The same
amount of dissolution medium was added in to make up for loss of samples taken.
The test usually took 30 minutes. After the last sample was drawn, the dissolution test
kept running for another hour. Then another sample was taken to confirm the
dissolution was complete and/or unchanged at the last sample time. After that, the
whole rack of solutions was cooled down to room temperature for further analysis.
The use of calcium ion selective electrode
•

Confirmation of electrode operation (slope)

Calcium standard solutions of 0.001M and 0.01M were prepared by diluting the
0.1M stock solution according to the following table.
Checking solution

0.1 M calcium stock solution (mL)

Distilled water (mL)

ISA* (mL)

I

1.0

100

2

II

10.0

100

2

Table 9. The preparation of standard solutions for the assessment of electrode operation.
*The ISA stands for ion strength adjuster, which is a NaCl solution.

After immersing the sensor part of the calcium ion selective electrode into those
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standard solutions, the potentials shown in the mV meter were then recorded. The
difference between the first and second potential reading was defined as the slope of
the electrode. The difference should be in the range of 25 to 30 mV/decade when the
solution temperature is 25±5°C.
This examination was required to be performed every time before measuring so
as to guarantee the reading’s sensitivity. Since the temperature of the solution
measured can affect the reading, the test was not started until the solution was cooled
down.

•

Calibrate the electrode

For calibration, the standard solutions at a series of concentrations at 0.01 M,
0.001 M and 0.0001 M were prepared by diluting 0.1M stock solution with distilled
water.

Standard solution
Calcium concentration (mol/L)

0.0001

0.001

0.01

0.1

0.1M calcium Stock solution (mL)

0.01

0.1

1

10

Distilled water (mL)

9.99

9.9

9

0

Ion strength adjuster (mL)

0.2

0.2

0.2

0.2

Table 10. The preparation of standard solutions for the calibration curve.

Then the potential at each concentration was measured by the calcium ion
selective electrode. The recorded readings were plotted on the linear axis against their
concentrations on the log axis. The linear region should cover from 0.0001 to 0.1M.
Typical calibration data and a representative profile is shown below:
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Calcium Electrode Calibration Curve
Calcium Concentration (M)

0.0001

0.001

0.01

0.1

Measurement (mV)

-67.3

-41.0

-5.3

25.5

Table 11. An example of typical readings in calibration.
40.0

y = 13.641Ln(x) + 56.5
R2 = 0.9969

20.0

mV

0.0
-20.0
-40.0
-60.0
-80.0
0.0001

0.001

0.01

0.1

1

Conc. (M)

Figure 2. A typical calibration curve with its regression equation.

The calibration curve may be affected by a variety of factors, such as room
temperature, the filling solution inside the electrode. Therefore, it was necessary to
calibrate the electrode every time before measurement of a set of samples. A
calibration equation was obtained to convert all potential readings (mV) into drug
concentration, and then release percentage.

•

Dissolution sample analysis

The dissolution samples were taken at specific intervals during the course of the
test. The sample solutions were first filtered into test tubes. After that, ion strength
adjuster (ISA) was added in each at a ratio of 1:50. When samples were mixed well
and cooled to room temperature, the electrode was then used to read the potential. By
using the calibration equation, all mV values were then turned into calcium
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concentrations, which were in the end converted into percentage of release by product
claimed content.

•

Conversion from potential (mV) to release percentage

A typical calibration equation has a form of y=aln(x)+b (example shown in
Figure 3, above), where y is the potential reading from the mV meter and x is the
concentration of calcium in solution. For a product, the calculation of relative drug
release percentage is:

Percentage _ of _ release =

EXP[( potential − b) / a] × medium _ volume × 40
labeled _ amount _ of _ elemental _ calcium
(Equation 3)

The dissolution profile is a curve showing the calcium release percentage over
time.

 Phase II - Dissolution test method development
Using the dissolution testing methodology described in “Methods – Phase I”, the
following studies were performed to improve the test’s sensitivity.
Our rationale is based on the dissolution theory of a pure substance which
follows the Noyes Whitney Equation:

dm
= k D A(C S − C B )
dt

(Equation 4)

Where dm/dt is the rate of dissolution, kD is the dissolution rate constant, A is the
surface area of the dissolving solid, CS is the saturation concentration of drug in
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diffusion layer and CB is the concentration of drug in dissolution media (or the bulk).
Dissolution rate constant kD is a function of the diffusion coefficient D and the
thickness of the diffusion boundary layer δ .
kD =

D

(Equation 5)

δ

Therefore, changing one or more variables in the dissolution conditions should,
in theory, affect the calcium release profile and the sensitivity of the test.

I. Increase the stirring speed

Increased agitation can reduce the thickness of the diffusion boundary layer δ .
Another effect is to facilitate tablets’ disintegration into fine particles which have a
larger surface area, A. In both ways, stirring speed can increase the dissolution rate.
In the test, a high speed stirrer (greater than 75 rpm) was used and the dissolution
was performed in a separate beaker. After the pH=1.0 simulated gastric medium was
heated to 37±0.5℃, the dissolution was performed one tablet at a time. Samples
were taken at specific intervals. Calcium released was measured by the calibrated
calcium ion selective electrode. Using the calibration equation, all potential readings
in mV were converted to release percentage. A dissolution profile was then generated
and compared with that from the USP standard test.

II. Larger volume dissolution test

Since the calcium dissolution appeared to saturation easily in the USP test, the
amount of calcium ions in solution, which could be measured by the electrode, was
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low and dissolution profiles of different products appeared too similar to discriminate.
Therefore, the volume of the dissolution medium was increased in attempt to achieve
a more complete dissolution.
In a larger sized beaker, the dissolution test was performed with different
medium volumes at 1×USP (0.9L) to 2×USP (1.8L) and 4×USP (3.6L), with
pH=1.0. Unknown as the speed of the stirrer (far greater than 75 rpm), its velocity
remained the same in all the revised dissolution tests. Calcium tablets were picked
randomly for this revised test.
Test in 8×USP was actually performed in 4×USP, i.e. 3.6L simulated gastric
fluid, with the sample tablets cut in half.
Products in different salt forms were investigated, NatureMade (calcium citrate),
PhosLo (calcium acetate), OsCal and Major (calcium carbonate). Since in 8×USP
test half-sized tablets were used, no products with coatings were tested.
After the medium was heated, one tablet was dropped and the test was started.
Sample solutions were drawn at specific time intervals. The calcium released was
measured by the calibrated calcium ion selective electrode. After this test was
repeated for six randomly selected tablets, dissolution profiles were generated and
compared with those obtained by the USP standard method.

III. Phosphate medium dissolution test

A phosphate dissolution medium was used on the premise that phosphate ion
would bind some calcium ions, and in this way, increase CS and promote the release
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of calcium. The phosphate buffer medium was prepared by dissolving KH2PO4 and
K2HPO4 at a ratio of 76.7:192.3 in distilled water, and was adjusted to pH=7.5 with
1N HCl or NaOH if necessary.
Tablets in different salt forms were tested, namely NatureMade (calcium citrate),
OsCal (calcium carbonate), and PhosLo (calcium acetate). For each product, six
randomly picked tablets were tested together, with three in phosphate buffer medium
and the other three in USP standard gastric fluid (pH = 1, 0.1 M HCl).
The test was performed by the USP standard II paddle method with the medium
volume of 0.9 L, stirring speed at 75 rpm. Sample solutions were drawn at specific
time intervals and measured by the calcium ion selective electrode. Recorded
potential data were then converted into release percentage. The dissolution profiles in
different media were compared.

IV. Surfactant medium dissolution test

The addition of surfactant is another approach to increase the relative solubility
of the calcium salt. In theory, increased CS will improve dissolution in both rate and
extent. When surfactant is added into 0.1N hydrochloric acid dissolution medium, the
pH may change accordingly, shown in Table 12.

Tween 80 Concentration
0
0.5%
1.0%
2.0%
5.0%
Final pH
1.0
1.4
2.1
2.7
4.2
Table 12. the change of pH at different surfactant concentrations
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10.0%
6.5

•

Optimization of surfactant level (0.1% ~2% )
The pH=1.0 simulated gastric fluid (0.1M HCl) was prepared and preheated to

37 ℃ in the dissolution apparatus. With continuous stirring, different amount of
Tween 80 were added into each beaker. The surfactant-containing media were
prepared at concentrations of 0%, 0.1%, 0.2%, 0.5%, 1% and 2%.
The dissolution test of six (6) NatureMade (calcium citrate) tablets was
performed at the stirring speed of 50 rpm. Samples were drawn out and measured by
the electrode. The dissolution profiles under every condition were compared.
The same test was also performed at the stirring speed of 75 rpm. The drug
release profiles were compared with those obtained at 50 rpm.

•

Optimization of surfactant level (10%~15%)
The pH=1.0 simulated gastric fluid (0.1M HCl) was placed in the dissolution

apparatus and preheated to 37℃. With continuous agitation, the dissolution media
were prepared with Tween 80 concentrations of 0%, 1%, 10%, 12.5%, and 15%.
Six (6) NatureMade (calcium citrate) tablets were tested at the stirring speed of
100 rpm, for as long as 240 minutes. Sample solutions were drawn out for
measurement of calcium release at specific time intervals.
For a more accurate measurement, standard calcium solutions with surfactant
were prepared for the electrode calibration. The composite of standard solutions is
shown below:
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a)
Standard solution with no Tween 80
Calcium concentration (mol/L)

0.0001

0.001

0.01

0.1

0.1M calcium stock solution (mL)

0.01

0.1

1

10

Distilled water (mL)

9.99

9.9

9

0

Ion strength adjuster (mL)

0.2

0.2

0.2

0.2

b)
1% Tween 80 standard solution
Calcium concentration (mol/L)

0.0001

0.001

0.01

0.1

0.1M calcium stock solution (mL)

0.01

0.1

1

10

Distilled water (mL)

9.99

9.9

9

0

Ion strength adjuster (mL)

0.2

0.2

0.2

0.2

0.102

0.102

0.102

0.102

Tween 80 (g)
c)

10% Tween 80 standard solution
10% Tween 80 standard solution

0.0001

0.001

0.01

0.1

0.1M calcium stock solution (mL)

0.01

0.1

1

10

Distilled water (mL)

9.99

9.9

9

0

Ion strength adjuster (mL)

0.2

0.2

0.2

0.2

Tween 80 (g)

1.02

1.02

1.02

1.02

d)
12.5% Tween 80 standard solution
Calcium concentration (mol/L)

0.0001

0.001

0.01

0.1

0.1M calcium stock solution (mL)

0.01

0.1

1

10

Distilled water (mL)

9.99

9.9

9

0

Ion strength adjuster (mL)

0.2

0.2

0.2

0.2

1.275

1.275

1.275

1.275

Tween 80 (g)
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e)
15% Tween 80 standard solution
Calcium concentration (mol/L)

0.0001

0.001

0.01

0.1

0.1M calcium stock solution (mL)

0.01

0.1

1

10

Distilled water (mL)

9.99

9.9

9

0

Ion strength adjuster (mL)

0.2

0.2

0.2

0.2

Tween 80 (g)

1.53

1.53

1.53

1.53

Table 13. The composite of surfactant-containing standard solutions for electrode calibration.

The calcium electrode was calibrated with corresponding standard solutions
every time before taking any measurement. The release profiles were generated and
compared. The condition under which the most release percentage was achieved was
selected as the best surfactant level.

•

Optimization of stirring speed
Since the dissolution rate decreased in a medium with high concentration of

surfactant, stirring speed was increased in an attempt to complete the dissolution in an
hour.
Six (6) tablets from products of three different calcium forms were tested by USP
standard II paddle method. Tween 80 concentration was at 0%, 10% and 15%. Stirring
speed was set at 100 rpm and 150 rpm. Samples were taken at specific time intervals,
and the test lasted 240 min to confirm complete dissolution. The calcium electrode
was calibrated in standard solutions with corresponding surfactant level. Dissolution
profiles for each experiment were generated and compared to pick the optimum
testing criterion.
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The optimized test conditions should be those under which the calcium salt can
reach complete dissolution, i.e. 100% release, or otherwise, reach saturation at a
higher release percentage and thus give a better sensitivity.

 Phase III - Testing of performance of commercially available calcium products:
Optimized vs. USP dissolution method.
I.

Physical tests

Tums quick-dissolve tablets were tested for their physical properties. Four
different Tums flavored tablets were in one bottle, sharing the same lot number, but
obviously made in different formulation. Therefore, each flavored type was tested
respectively and compared. Physical tests included weight variation, hardness,
thickness and friability. All are described in detail in Phase I method part. Note that
for chewable tablets, friability testing is not necessary but only for the purpose of
comparison with regular tablets. Since there are not enough tablets (less than 6) for
the yellow ones, there is no result for that flavor. The traditional chewable tablets
were also tested.

II.

Disintegration tests

Again, this is not necessary for chewable tablet but only for the purpose of
comparison. The length of Tums tablets is greater than 18 mm and therefore was
tested by Apparatus B, with the three chamber basket. Tests were performed only in
distilled water. The traditional chewable tablets and “quick dissolve” tablets were
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compared.

III. Dissolution tests under the conditions of both the USP method and the
revised method

In the USP condition, the dissolution medium was pH=1.0 hydrochloric acid
solution; stirring speed was at 75 rpm; three tablets of the same flavor (four flavors
altogether) were tested. In the revised method, dissolution medium was 10% Tween
80 in 1N hydrochloric acid solution. With all other conditions the same, the
dissolution profiles by these two methods were compared. Traditional Tums chewable
tablets were also tested in the same way for comparison.
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References for Chapter III

1. USP 28/NF 23 General Chapters. Chart 12. Dietary Supplement Products. 2196
2. USP 28/NF 23 General Chapters. <1216> DISINTEGRATION AND
DISSOLUTION OF DIETARY SUPPLEMENTS. 2778-80
3. USP 28/NF 23 General Chapters. <701> DISINTEGRATION. 2411-2
4. USP 28/NF 23 General Chapters. <2040> TABLET FRIABILITY. 2745
5. USP 28/NF 23 General Chapters. <2091> WEIGHT VARIATION OF DIETARY
SUPPLEMENTS. 2780-1
6. USP 28/NF 23 General Chapters. <905> UNIFORMITY OF DOSAGE UNITS.
2503
7. USP 28/NF 23 General Chapters. <711> DISSOLUTION. 2412-4
8. USP 28/NF 23 Official Monographs. Calcium Carbonate Tablets. 320-1

* USP 28/NF 23 is for the year of 2005.
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Chapter IV

Results and Discussion

 Phase I - Testing of performance of commercially available calcium
products
I.

Physical tests

Physical properties of tablets can reflect the quality of the products. Especially, the
tablets’ hardness and friability are factors that can affect the disintegration rate and their
dissolution behavior.

Physical properties
Brand
Salt form
Elemental calcium content
Lot

NatureMade

Leader

OsCal

CVS

PhosLo

Walgreens

HiCal

Carbonate

Carbonate

Carbonate

Carbonate

Acetate

Carbonate

Carbonate

500mg

600mg

500mg

600mg

169mg**

600mg

200mg**

NB10929

1HN0579

1G0925

OMB0304

POL336

0F01786

OCO1486

Weight

Mean

1.354

1.723

-*

1.753

0.715

1.716

1.508

Variation (g)

Std Dev

0.023

0.025

-*

0.009

0.007

0.027

0.007

Mean

0.3541

0.2917

0.2713

0.3054

0.2155

0.2770

0.2689

Std Dev

0.0040

0.0034

0.0023

0.0013

0.0011

0.0017

0.0020

Mean

19.3

23.3

31.3

8.4

7.6

31.9

26.3

Std Dev

2.1

2.2

2.2

1.2

0.8

2.2

1.6

0.1%

fail

0.0%

Fail

0.8%

fail

0.0%

Thickness (inch)

Hardness (kP)
Friability

Table 14. Physical properties for each calcium supplement product.
* There were not enough tablets for weight variation test of OsCal and thickness and hardness
test of Tums Yellow.
** The elemental calcium of PhosLo and HiCal was calculated from its labeled amount of
calcium salt.
*** Chewable tablets (Tums) are covered in Phase III results.
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From this table, the standard deviation of weight variation, thickness, and hardness
of all products were low, indicating that a good conformity within batch has been
achieved.
According to our results, Leader, CVS and Walgreens failed the friability tests,
since there was at least one tablet broken during the test. For Tums products, since they
are chewable tablets, which are designed to easily break apart, their tablet hardness is
low and it is not expected that they would pass the friability test. They are typically so
friable that shaking the bottle by hand can lead to some breakage. Tums were the only
chewable calcium products tested.
For all regular tablets, different products had different hardness, ranging from 7.6
to 31.9 kP. It is anticipated that extremes in hardness may affect disintegration
performance primarily and dissolution, secondarily.

II.

In vitro disintegration

A. Comparison of Apparatus for large tablets
First, the disintegration behavior in standard Apparatus A and Apparatus B was
investigated to compare the two apparatus and to see whether a significant change in
disintegration occurs for tablets longer than 18 mm. Tests were performed in simulated
gastric fluid (SGF), simulated intestinal fluid (SIF) and distilled water (DW). The
disintegration in both standard apparatus was compared and related to the length of the
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tablet. The results are shown below in Table 15 and Figure 3.
Length

Brand

(mm)

SGF

SIF

DW

Apparatus A

Apparatus B

Apparatus A

Apparatus B

Apparatus A

Apparatus B

AVG

SD

AVG

SD

AVG

SD

AVG

SD

AVG

SD

AVG

SD

Caltrate

20.4

22.15

2.00

9.42

0.99

>60

-

20.93

1.66

31.63

1.83

20.04

1.83

Walgreens

20.5

21.94

2.76

9.14

0.75

27.11

2.23

18.88

2.23

26.74

1.95

17.04

1.17

HiCal

19.6

1.24

0.18

1.75

0.19

1.56

0.11

2.25

0.41

1.31

0.11

1.77

0.07

Leader

19.3

9.78

0.82

1.63

0.15

15.03

1.14

2.58

0.15

10.50

0.94

2.61

0.20

OsCal

19.2

12.19

0.42

11.63

1.34

12.93

0.21

12.83

0.99

12.88

0.25

12.54

0.85

Table 15. Length of the tablets and their disintegration profile in Apparatus A and B.
* AVG: average time (min); SD: standard deviation (min).

For Caltrate, its disintegration in SIF by Apparatus A was not complete in 30
minutes, so its test was extended to 60 minutes. After 60 minutes when complete
disintegration still was not achieved, the test was stopped. Therefore, no standard
deviation was shown in the table above.

Disintegration time (min)

40.00

30.00

20.00

10.00

0.00

Caltrate

Walgreens

HiCal

Leader

SGF A

22.15

21.94

1.24

9.78

OSCAL
12.19

DW A

31.63

26.74

1.31

10.50

12.88

SIF A

60

27.11

1.56

15.03

12.93

SGF B

9.42

9.14

1.75

1.63

11.63

DW B

20.04

17.04

1.77

2.61

12.54

SIF B

20.93

18.88

2.25

2.58

12.83

Figure 3. Comparison of disintegration in SGF, DW and SIF by Apparatus A and B

From these results, it is seen that for larger tablet supplements, there is a difference
of disintegration time between Apparatus A and B, with Apparatus B causing a faster
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disintegration. This difference is not significant for a fast disintegrating product, like
RiteAid HiCal. Though not the primary focus of this study, of note also in this data set
is the sensitivity of all five products’ disintegration time to pH (regardless of the
apparatus) with disintegration time increasing with increasing pH.
This difference between the results from the two apparatus is likely partly caused
by the different movement of the disintegration medium of the medium across the
surface of the tablets. In Apparatus B, the tablet can lie flat on the bottom mesh plate.
The sufficient space between the tablet and basket allows smooth flow across the tablet,
which will facilitate the wearing off of coating material (if there is any), ultimately
eroding the surface into a coarse state and helping tablet disintegration. Experiencing
the same hydrodynamics, tablets show less deviation in disintegration time.
For Apparatus A, however, longer tablets may stand at an angle against the wall.
Some may not be able to move up and down freely with the current of the medium, but
stick at a position in the basket and move with it. Some others may still be able to be
carried along with the current, but collisions with the wall can happen and the
orientation of the tablet is random. The irregular current (i.e. Hydrodynamic effects)
around tablets and the limited movement would hamper the wearing off of coating
material, and/or retard the disintegration processes in some other manner. This also
appears to lead to a greater deviation in tablet disintegration time.
As a result, as with pharmaceutical products, it appears also that nutraceutical
tablets need to be measured by length first to decide the appropriate device for
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disintegration testing.

B. Disintegration as a function of pH
The following research shows the disintegration performance of all eight products
in traditional tablet formulation. The disintegration of the Tums chewable product is not
included in this data set.

Brand

Simulated Gastric Fluid

Simulated Intestinal Fluid

Distilled Water

AVG

SD

AVG

SD

AVG

SD

Caltrate

9.42

0.99

20.93

1.66

20.04

1.83

Walgreens

9.14

0.75

18.88

2.23

17.04

1.17

HiCal

1.75

0.19

2.25

0.41

1.75

0.07

Major

1.36

0.20

3.08

0.38

3.78

0.21

CVS

7.72

3.95

10.89

8.32

7.28

6.79

PhosLo

3.32

0.38

4.86

0.20

3.06

0.36

Leader

1.63

0.15

2.58

0.15

2.61

0.20

OsCal

11.63

1.34

12.83

0.99

12.54

0.85

Table 16. Disintegration data of each calcium supplement.
AVG: average disintegration time (min); SD: standard deviation (min)

Disintegration time (min)

25.00
20.00
15.00
10.00
5.00
0.00

Caltrate

Walgreens

HiCal

Major

CVS

PhosLo

Leader

OSCAL

SGF

9.42

9.14

1.75

1.36

7.72

3.32

1.63

11.63

DW

20.04

17.04

1.75

3.78

7.28

3.06

2.61

12.54

SIF

20.93

18.88

2.25

3.08

10.89

4.86

2.58

12.83

Figure 4. Disintegration profile of each calcium supplement
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The USP required medium for calcium supplements is distilled water. From the
result, all eight products are compliant with this requirement. Although they differ
significantly in their disintegration rate, all of them can successfully pass through the
mesh within thirty (30) minutes in all the three different pH media.
Some of the samples disintegrate extremely fast (in two to three minutes). Brands
in this category are HiCal, Major and Leader. For them, no significant change has been
observed in the different media, perhaps due to their short disintegration time. For
relatively slow disintegrating products, such as Caltrate and Walgreens, their
disintegration can last as long as 20 min. Higher pH media, namely distilled water and
simulated intestinal medium, significantly prolonged their disintegration. In general, all
products disintegrated in simulated gastric fluid faster than under other conditions. This
would be the preferred performance, since calcium supplements should disintegrate and
begin dissolving in the stomach, when taken orally.
In relation to the products’ physical properties (shown in Table 13), friability does
not appear to correlate with disintegration time. For hardness, some connection is
observed. Soft tablets like CVS and PhosLo exhibit a faster disintegration, while harder
ones such as Walgreens and OsCal take a longer time to disintegrate. The significant
variability seen on CVS disintegration could be in part, due to the products’ poor
friability and low hardness.
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III.

In vitro dissolution – USP conditions

Some commercially available calcium products (as shown in table 7) were tested
using the USP II standard paddle test. Six (6) tablets were tested in the medium of
pH=1.0 hydrochloric acid. The percentage of active elemental calcium (based on salt
and product labeling) dissolved to the labeled amount is calculated and graphed out as
dissolution profiles, which are shown below.
RiteAid HiCal

Major
70.0%

160.0%
release percentage

release percentage

60.0%
120.0%

80.0%
40.0%

50.0%
40.0%
30.0%
20.0%
10.0%

0.0%

0.0%
0

5

10

15

20

25

30

0

35

5

10

15

OSCAL

25

30

35

Walgreens

30.0%

20.0%
release percentage

release percentage

20

time (min)

time (min)

20.0%

10.0%

15.0%

10.0%
5.0%

0.0%

0.0%
0

5

10

15

20

25

30

35

0

5

10

15

time (min)

20

25

30

35

25

30

35

time (min)

CVS

PhosLo

30.0%

40.0%
release percentage

release percentage

25.0%
20.0%
15.0%
10.0%
5.0%

30.0%

20.0%
10.0%

0.0%

0.0%
0

5

10

15

20

25

30

35

0

5

10

15

time (min)

20

time (min)

NatureMade Products

release percentage

40.0%

30.0%

20.0%

10.0%

0.0%
0

5

10

15

20

25

30

35

Time (min)
Calcium Citrate & Vit D

Calcium Citrate

Figure 5. Calcium supplement dissolution profiles by USP standard paddle method.
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From the graphs shown in Figure 6, except for RiteAid HiCal, none of the other
products reached a final drug release of over 50%. Some products, Major and OsCal
namely, experienced a sharp increase (quick dissolution, or quick drug release) in the
first few minutes, producing a notable initial peak. After this, the calcium concentration
in solution dropped to a lower level and kept relatively unchanged till the end of the
study. This may indicate an oversaturated initial state upon dissolution or a
method-related aberration, due to stirring speed.
For some other products like CVS, PhosLo, Walgreens and NatureMade, their
initial release does peak. It takes from 5 to 10 minutes for them to reach a relatively
stable value, where a plateau is then reached, indicating the maximum release amount.
This irregular dissolution behavior may be a result of the low solubility of calcium
salts, even in acidic media. The structure and solubility of the three calcium salts are
shown below:
Salt form

Formula

Calcium acetate

Structure

C4H6CaO4

Molecular
weight
158.169

Solubility in
water 25
37.4%

Calcium carbonate

CaCO3

100.0892

0.0015%

Calcium citrate

C12H10Ca3O14

498.4426

0.22%

Calcium Chloride

CaCl2

110.99

74.5%

Table 17. The chemical properties of the three calcium salt forms.1
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On the other hand, the dissolution of calcium tablets can neutralize the some acid
and make the environment less acidic. The calcium amount in the dissolution medium is
thus limited. This may get reflected for a quick releasing product in an over saturation
of the solvent (i.e. dissolution peak) that leads to calcium precipitation and subsequent
dissolution to a less saturated state. It can also be inferred from the curve that the
solubility of carbonate is lower than other salt forms since, except for one case, it
reaches a lower release percentage, which conforms to the reference data. It can also be
observed that most calcium carbonate products release faster than other salt forms.
This result (shown in Figure 6) indicates that the current USP dissolution testing
methodology is inadequate in case of those less soluble drugs. To obtain a sensitive and
reproducible analysis result, efforts should be made to improve the dissolution, allowing
for greater calcium release in the dissolution medium. The following revised tests were
then performed, in order to modify this test method.

 Phase II – Development of an optimized dissolution testing
methodology for calcium-based supplements
I.

Increased speed, larger volume dissolution

Different calcium salts have been tested by the increased volume method. Six (6)
tablets of each product were tested in the medium of pH=1.0 hydrochloric acid. The
volume of dissolution media increased from 1×USP (0.9 L), to 2×USP (1.8 L), 4×
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USP (3.6 L) and 8×USP (half tablet in 3.6L). The stirring speed was increased to
nearly 500 rpm. The dissolution profiles were compared with each other. Profiles are
shown below.

Dissolution Profiles of OSCAL
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Figure 6. Calcium supplements’ dissolution profiles in increased speed and larger volume tests.

Since the dissolution test in bigger sized beakers cannot be performed
simultaneously for one product, it is believed that the change in medium and other
factors contribute to the relatively large deviation. In order to better observe the change
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due to volume change, the deviation bars are removed in the following figure to
compare the shifting trend.
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Figure 7. Calcium supplements’ dissolution profiles in increased speed and larger volume tests.

For this revised paddle testing method, increased stirring speed and volume of
dissolution medium did improve the dissolution. Although the trend of increased drug
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release was observed, yet such improvement was not as good as anticipated; the result is
still not discriminating. Although the deviation at each sample point can be reduced by
proper experiment design, it is yet not practical to increase the medium to an even larger
volume to reach a better drug release. Under these new conditions, the initial peak/burst
seen with the carbonate products with the USP method was eliminated.

II.

Phosphate binding medium

A phosphate dissolution medium was used here on the premise that phosphate ion
will bind some calcium ions, and in this way, promote calcium release.
The different calcium salts were tested in pH=7.5 phosphate medium by the USP
paddle method with the stirring speed at 50 rpm. The profiles are compared with those
in acidic media.
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Figure 8. Calcium supplements’ dissolution profiles in phosphate buffer medium

From the figures above, the phosphate buffer media significantly failed to improve
the dissolution of less soluble calcium salts. Although phosphate binding may be a
favorable factor to facilitate dissolution, this medium’s high pH (7.5) may have
contributed more in limiting the calcium release in the experiments.
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III.

Surfactant medium

Surfactant molecules are by nature bipolar. They usually contain a polar head
group which is hydrophilic, and a hydrophobic hydrocarbon chain tail. When placed in
water, these amphiphiles then form clusters of molecules known as micelles, which help
the less soluble drug particles dissolve in water.

The structure of Tween 80
In our preliminary experiments, two popular surfactants, SLS and Tween 80, were
used. However, since SLS had some salt effect with calcium samples and formed
precipitation instantly, Tween 80 became a standard surfactant in our following tests.
A. Optimization of surfactant level I
1. NatureMade calcium carbonate release profile at 50 rpm.

Relative % of Calcium Dissolved in Each Sample
Time (min)

Surfactant concentration
0%

0.1%

0.2%

0.5%

1.0%

2.0%

0.0

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

2.5

9.71%

4.06%

2.90%

7.93%

-

1.40%

5.0

12.75%

8.57%

9.26%

16.48%

4.18%

5.31%

7.5

14.78%

13.05%

13.78%

26.50%

12.65%

11.23%

10.0

17.27%

16.87%

17.54%

31.69%

21.23%

19.76%

15.0

20.33%

20.02%

26.29%

37.32%

32.13%

30.87%

20.0

21.81%

23.58%

30.01%

41.29%

37.37%

37.37%

25.0

21.47%

23.39%

29.32%

42.27%

40.47%

42.45%

30.0

20.49%

23.03%

30.48%

44.98%

43.14%

42.79%

Infinite

18.25%

19.76%

24.50%

45.97%

49.39%

48.61%

Table 18. Calcium supplements’ dissolution in surfactant containing media 50 rpm
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Dissolution profile of NatureMade Calcium Carbonate in Tw een 80 Medium
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Figure 9. Calcium supplements’ dissolution profiles in surfactant containing media 50 rpm

This test was intended to be a preliminary estimation of the impact of surfactant on
calcium salt dissolution. Therefore, no repetitive runs were performed for accurate
measurement. The results show that the dissolution is both improved and more
characteristic with the increasing amount of surfactant. The initial release rate may be
lowered due to the pH change, from 1 to about 3, by addition of Tween 80. The release
extent, however, is significantly improved. Since our aim is to reach the maximum
release amount in thirty (30) minutes, the stirring speed is also increased in the
following tests and higher level of surfactant is also tested.

2. Drug release profile at 75 rpm.

Since the dissolution rate was decreased with the addition of surfactant, the stirring
speed was increased to 75 rpm to reduce this effect. At the same time, higher
concentration at 5% surfactant was included in the test to see whether the dissolution
extent could be further enhanced.
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Relative percentage of Calcium Dissolved in Each Sample
Time (min)

Surfactant concentration
0%

0.1%

0.2%

1%

2%

5%

0.0

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

2.5

3.61%

3.36%

3.07%

2.69%

1.59%

2.20%

5.0

6.87%

4.76%

7.96%

7.22%

5.21%

5.98%

7.5

8.70%

7.83%

16.30%

12.46%

11.86%

19.82%

10.0

10.41%

16.84%

22.40%

16.98%

17.98%

30.53%

15.0

10.25%

16.30%

23.33%

23.91%

33.12%

40.93%

20.0

10.33%

16.57%

24.30%

29.79%

45.14%

44.41%

25.0

11.21%

17.40%

25.52%

29.31%

44.77%

46.26%

30.0

12.98%

16.84%

23.91%

29.07%

46.63%

47.79%

Infinite

11.11%

18.42%

23.52%

29.55%

45.88%

48.18%

Table 19. Calcium supplements’ dissolution in surfactant containing media 75 rpm

Dissolution Profile of NatureMade Calcium Carbonate
in Different Level of Surfactant Mediums
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Figure 10. Calcium supplements’ dissolution profiles in surfactant containing media 75 rpm

Again, the test provided an estimation of the extent to which surfactant would
improve the dissolution. No repetitive runs were performed in this experiment. The
results showed no obvious difference in release profiles from 50 rpm and 75 rpm
experiments, except in the case of 2% surfactant. However, increased amount of Tween
80 improved the dissolution extent while slowing down the initial phase of release. For
calcium dissolution in 2% and 5% media, it was not clear whether the dissolution was
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completed in 30 minutes. Therefore, it was necessary to run the dissolution at even
higher stirring speed when surfactant concentration is high.
B. Optimization of surfactant level II and optimization of stirring speed
Based on the previous results, the following experiments were performed under
conditions at higher stirring speeds (100 and 150 rpm). Higher Tween 80 concentrations
were also tested to determine the upper limit of surfactant level.
1.

Optimized Surfactant Level for NatureMade calcium carbonate
Release percentage of Calcium in Each Sample
Tween 80 0%

Tween 80 10%

Tween 80 12.5%

Tween 80 15%

Tween 80 10%

Tween 80 15%

100rpm

100rpm

100rpm

100rpm

150rpm

150rpm

Time (min)

AVG

SD

AVG

SD

AVG

SD

AVG

SD

AVG

SD

AVG

SD

0.0

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

2.5

1.37%

0.22%

3.64%

1.01%

1.57%

0.58%

1.27%

0.36%

1.92%

0.92%

1.25%

0.36%

5.0

3.42%

0.44%

6.04%

1.49%

4.81%

0.96%

4.43%

0.68%

4.76%

0.78%

5.95%

0.48%

7.5

10.69%

1.71%

14.93%

2.93%

13.63%

1.53%

11.49%

0.84%

16.88%

2.29%

14.08%

0.32%

10.0

19.28%

2.92%

26.72%

2.68%

23.60%

2.69%

19.83%

1.25%

30.56%

4.87%

23.07%

0.87%

15.0

18.98%

0.86%

38.32%

1.76%

38.04%

1.00%

31.78%

1.16%

44.50%

6.42%

33.41%

2.32%

20.0

19.22%

0.97%

44.12%

1.47%

42.12%

2.95%

40.21%

2.21%

48.45%

1.92%

42.63%

2.62%

25.0

19.33%

0.90%

48.63%

2.22%

46.94%

4.55%

43.56%

3.05%

49.33%

0.91%

47.39%

1.98%

30.0

19.20%

0.20%

50.82%

1.27%

48.69%

4.77%

44.63%

3.06%

49.63%

1.15%

49.04%

2.92%

60.0

19.79%

0.00%

54.21%

3.17%

52.13%

3.20%

48.57%

2.22%

49.80%

1.83%

49.35%

3.17%

90.0

19.74%

0.91%

55.09%

2.33%

51.67%

3.62%

49.16%

2.10%

49.49%

1.38%

49.33%

2.73%

120.0

19.87%

1.14%

56.01%

2.18%

53.55%

2.49%

49.78%

2.63%

49.63%

0.95%

49.60%

1.70%

150.0

19.93%

1.18%

56.48%

2.29%

53.05%

2.18%

50.09%

2.86%

49.95%

1.88%

49.47%

2.32%

180.0

20.00%

1.24%

56.65%

2.64%

53.86%

1.85%

50.69%

2.36%

51.04%

1.90%

49.30%

1.44%

210.0

20.00%

1.41%

56.33%

2.35%

53.70%

2.12%

50.85%

2.43%

49.95%

1.62%

50.08%

2.49%

240.0

20.26%

1.67%

55.39%

1.93%

54.03%

2.04%

51.18%

3.14%

50.71%

1.23%

50.70%

2.81%

Table 20. NatureMade calcium carbonate’s dissolution profile in optimized test.
* AVG: average percentage; SD: standard deviation. total test runs n=3
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Optimized Surfactant Level for NatureMade Calcium Carbonate

release percentage
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Tween 80 0% 100rpm

Tween 80 10% 100rpm

Tween 80 12.5% 100rpm

Tween 80 15% 100rpm

Tween 80 10% 150rpm

Tween 80 15% 150rpm

Figure 11. NatureMade Calcium Carbonate’s dissolution profile in optimized test.

In the figure above, the deviation bars of the experiments are not shown for easier
reading. The results show that the improvement of dissolution from increasing stirring
speed is limited. For calcium carbonate, the testing with a speed of 100 rpm is
sufficiently high, and the optimum concentration of Tween 80 is 10%. Further increase
does not achieve better performance/greater dissolution.
2.

Optimized Surfactant Level for Major Calcium Carbonate

The dissolution conditions used in the test for Major calcium carbonate and
PhosLo calcium acetate were picked from the previous result of NatureMade calcium
carbonate. Stirring speed was tested at 100 and 150 rpm; surfactant concentration was
set at 10% and 15%. The dissolution in surfactant containing medium was compared.
For Major calcium carbonate, the results are shown below:
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Relative percentage of Calcium Dissolved in Each Sample
Tween 80 0%

Tween 80 10%

Tween 80 10%

Tween 80 15%

100rpm

100rpm

150rpm

150rpm

Time (min)

AVG

SD

AVG

SD

AVG

SD

AVG

SD

0.0

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

2.5

11.04%

1.72%

4.39%

1.23%

5.13%

1.15%

4.19%

0.33%

5.0

12.64%

1.05%

8.40%

1.10%

8.98%

1.91%

6.45%

1.18%

7.5

13.31%

0.96%

10.76%

0.79%

10.83%

1.09%

9.40%

0.79%

10.0

13.65%

0.13%

13.14%

1.15%

14.20%

1.91%

12.13%

0.49%

15.0

13.73%

0.26%

15.32%

0.66%

15.29%

1.72%

13.83%

0.59%

20.0

13.96%

0.18%

16.39%

1.44%

16.71%

1.22%

14.82%

0.78%

25.0

14.00%

0.24%

16.71%

1.40%

16.98%

1.36%

15.40%

1.15%

30.0

14.35%

0.42%

16.72%

1.62%

17.18%

1.35%

16.11%

1.54%

60.0

14.68%

0.67%

17.07%

1.34%

17.29%

1.35%

16.47%

1.60%

90.0

14.64%

0.79%

16.88%

1.12%

17.41%

1.64%

16.68%

1.54%

120.0

14.51%

0.52%

16.75%

1.29%

17.41%

1.62%

16.61%

1.38%

150.0

14.67%

0.49%

16.90%

1.53%

17.77%

1.42%

16.79%

1.64%

180.0

14.63%

0.48%

17.14%

1.64%

17.50%

1.33%

16.73%

1.59%

210.0

14.47%

0.46%

16.90%

1.62%

17.61%

1.41%

16.77%

1.40%

240.0

14.67%

0.45%

16.98%

1.42%

17.49%

1.19%

16.95%

1.67%

Table 21. Major Calcium Carbonate’s dissolution profile in optimized test.
Optimized Surfactant Level for
Major Calcium Carbonate
50.00%

release percentage

40.00%
30.00%
20.00%
10.00%
0.00%
0.0

30.0

60.0

90.0

120.0

150.0

180.0

210.0

time (min)
Tween 80 0% 100rpm
Tween 80 10% 100rpm
Tween 80 10% 150rpm
Tween 80 15% 150rpm

Figure 12. Major Calcium Carbonate’s dissolution profile in optimized test.
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240.0

3.

Optimized Surfactant Level for PhosLo Calcium Acetate

For PhosLo calcium acetate, the results are shown below:
Relative percentage of Calcium Dissolved in Each Sample
Tween 80 0%

Tween 80 10%

Tween 80 10%

Tween 80 15%

100rpm

100rpm

150rpm

150rpm

Time (min)

AVG

SD

AVG

SD

AVG

SD

AVG

SD

0.0

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

2.5

15.59%

3.34%

3.57%

0.70%

5.29%

1.26%

2.84%

0.72%

5.0

16.95%

1.64%

5.37%

1.87%

12.31%

3.33%

4.83%

0.64%

7.5

17.91%

1.85%

7.15%

2.74%

18.58%

3.35%

10.05%

2.35%

10.0

17.53%

1.13%

9.69%

2.47%

24.33%

1.78%

19.10%

3.13%

15.0

17.18%

0.64%

13.32%

2.40%

25.88%

2.44%

22.29%

1.27%

20.0

17.47%

0.70%

16.44%

1.07%

26.02%

2.09%

22.49%

2.50%

25.0

18.04%

1.43%

19.42%

3.72%

26.61%

2.76%

22.81%

2.99%

30.0

17.89%

1.45%

21.69%

3.14%

26.44%

2.66%

23.09%

2.88%

60.0

18.44%

1.57%

24.01%

2.13%

27.15%

2.24%

22.98%

3.27%

90.0

18.55%

1.63%

26.11%

3.75%

26.99%

2.28%

23.75%

2.96%

120.0

18.44%

2.24%

26.25%

2.80%

26.99%

2.40%

24.16%

3.41%

150.0

18.64%

1.37%

25.80%

3.47%

27.02%

2.85%

24.52%

3.26%

180.0

18.17%

1.94%

26.24%

3.64%

26.61%

2.76%

24.39%

3.53%

210.0

18.15%

1.74%

26.46%

2.56%

26.50%

2.18%

24.77%

3.45%

240.0

18.55%

1.71%

27.04%

2.30%

27.43%

2.76%

24.55%

2.64%

Table 22. PhosLo Calcium Acetate’s dissolution profile in optimized test.
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Optimized Surfactant Level for
PhosLo Calcium Acetate

release percentage

40.00%

30.00%

20.00%

10.00%

0.00%
0.0

30.0

60.0

90.0

120.0

150.0

180.0

210.0

240.0

time (min)
Tween 80 0% 100rpm

Tween 80 10% 100rpm

Tween 80 10% 150rpm

Tween 80 15% 150rpm

Figure 13. PhosLo Calcium Acetate’s dissolution profile in optimized test.

The best testing method for Naturemade calcium carbonate was used for both
Major and PhosLo. The surfactant level was compared between 10% and 15%, while
stirring is between 100 and 150 rpm. From the data shown in Figures 13 and 14, the
dissolution of calcium has increased significantly compared with that in plain medium
(with no surfactant). And again, there is no meaningful improvement when the stirring
speed is higher that 100 rpm or the surfactant level higher than 10%.
The general structure of a surfactant includes a hydrophilic portion (usually a polar
or ionic group, water soluble) and a hydrophobic portion (usually a long fatty or
hydrocarbon chain, water insoluble). This dual functionality helps wetting and
spreading across the particle surface. The relative solubility is thus improved. The
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results above seem to confirm this. The addition of surfactant increases the extent of
drug release significantly, making the test more sensitive. The results show that the
upper limit of surfactant (Tween 80) for optimization is about 10%. The salt most
sensitive to this effect appears to be calcium carbonate.
When the surfactant is added into the solution, the dissolution medium becomes
less acidic. In the lack of the low pH environment (a low pH facilitates tablet
disintegration and increase the surface area of calcium available for dissolution), the
dissolution rate is then decreased, taking longer time to reach saturation. Faster stirring
can help reduce this delay. The results show increased agitation can make the
dissolution completed in 30 minutes, a typical length of time for the dissolution test.
The optimum stirring speed should be decided based on the release rate of each product.
For calcium acetate, 150 rpm stirring is favored, while in other two products, no
significant change can be seen between 100 and 150 rpm.
In conclusion, the optimum testing methodology should be:


Calcium carbonate tablet

Medium: 10% Tween 80 in 1N hydrochloric acid, 900 mL
Apparatus 2: 100 rpm
Time: 30 minutes


Calcium acetate tablet

Medium: 10% Tween 80 in 1N hydrochloric acid, 900 mL
Apparatus 2: 150 rpm
Time: 30 minutes
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As for the tolerance of the test, even under this optimum condition, it is not
realistic to require 75% (Q) dissolution in the experiment. As seen in the results
aforementioned, around 50% calcium release is the best to be achieved.

 Phase III – Use of revised method to evaluate dissolution of calcium
supplement tablets
1. Physical tests
Brand
Salt form

Tums
Pink

Tums
Orange

Tums
Brown

Tums
Yellow

Carbonate

Carbonate

Carbonate

Carbonate

Elemental calcium content

300mg

Lot

4D19

Weight
Variation (g)
Thickness (inch)
Hardness (kP)

Mean

1.894

1.896

1.886

1.885

Std Dev

0.007

0.014

0.008

0.006

Mean

0.2194

0.2167

0.2205

-

Std Dev

0.0007

0.0008

0.0083

-

Mean

11.1

11.2

12.6

-

Std Dev

0.5

0.7

0.8

-

Table 23. Physical properties of Tums calcium carbonate chewable tablets
* Not enough tablets for physical tests of Tums Yellow.
** Elemental calcium content was calculated from the products’ labeled content CaCO3 750mg.
*** The tested Tums is the chewable, quick dissolve product.

Since there are four different flavor tablets in one bottle (using the same lot
number), we separated them and tested these individually.
According to the results, the formulation variation of different flavored tablets does
not result in significant change in their physical properties. Therefore, the amount of
flavor and color additive are limited and do not appear to affect the tablets’ physical
properties significantly. Since the processing parameter and other excipients for each
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flavor may be the same, which guarantees the conformity within the batch, it is
reasonable for the manufacturer to use the same lot number for all four flavor tablets.

2. Disintegration tests
Chewable tablets are not formulated to disintegrate. (They have no inherent
disintegration behavior, as they are chewed.) These studies were still performed,
however, for purpose of comparison. The disintegration medium used was distilled
water, pH=5-7. The disintegration of the tested tablet cannot significantly change the
pH of the medium.
Tums Pink

Tums Orange

Tums Brown

Tums Yellow

4D19

4D19

4D19

4D19

Time (min)

9.9

7.8

8.6

7.1

Std Dev (min)

0.4

0.0

0.2

0.2

Brand
Lot

Table 24. Disintegration time for Tums calcium carbonate chewable tablets.

Of note is that this product is formulated to be used both as a calcium supplement
and as an anti-acid tablet. In the use as an antacid, the goal is to achieve quick
disintegration, meaning that products will break into fine powders in very short time
and thus create more surface area to contact and absorb gastric acid. This explains its
quick disintegration, less than ten (10) minutes, independent of being chewed.

3. Dissolution tests
All four flavored tablets were tested by both USP standard method and the
optimized surfactant medium method. These chewable tablets were quick to dissolve.
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Our preliminary study showed their dissolution reached maximum in less than thirty (30)
minutes at a stirring speed of 50 rpm in a surfactant containing medium. The
comparison of dissolution by the two methods is shown below:

Dissolution profile of Tums Pink
Calcium Carbonate in Tween 80 Medium

100.00%

100.00%

80.00%

80.00%
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Dissolution profile of Tums Orange
Calcium Carbonate in Tween 80 Medium
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Dissolution profile of Tums Brown
Calcium Carbonate in Tween 80 Medium
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Dissolution profile of Tums Yellow
Calcium Carbonate in Tween 80 Medium
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Figure 14. Dissolution profiles of Tums chewable tablets in USP and revised testing method.

The results show that in all four flavored products, the extent and rate of
dissolution again appear limited by the poor solubility of calcium carbonate. The
products cannot release over 70% calcium in USP standard method. When surfactant is
added in high concentration, for all four flavored tablets, the calcium release can reach
over 70% in 30 minutes. In this case, the addition of Tween 80 successfully makes the
tolerance in USP become an attainable goal.
Because the drug, when used as an antacid, is supposed to have its effect in the
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stomach instead of being absorbed into the blood for a systemic effect, enhanced
dissolution is not required. However, since this product is being recommended for use
in the prevention of osteoporosis (i.e. systemic effect), complete dissolution would be
desired.
4. The comparison of dissolution profiles using optimized and USP conditions.
The dissolution profiles of NatureMade, Major and PhosLo which were obtained
by using both optimized and USP conditions were compared.

Comparison of dissolution profiles for PhosLo
calcium acetate

release percentage
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Revised method

30.0

35.0

Comparison of dissolution profiles for NatureMade
calcium carbonate
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Comparison of dissolution profiles for Major
calcium carbonate
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Figure 15. The comparison of dissolution profiles using optimized and USP conditions.

From the figures above, a significant improvement can be observed in the revised
test. This result confirmed the optimized methodology was an improvement over USP,
showing greater dissolution and increased sensitivity.
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Chapter V

Summary and Conclusions

With the increasing popularity of regularly using calcium supplements with the
intention of health benefits, the quality of these products is coming under growing
scrutiny. Concerns in their absorption and effectiveness call for a closer look at the
current testing methods for them. In our research, the pharmaceutical quality of
several commercially available calcium products was examined; a revised dissolution
testing methodology was developed and proposed; and the testing of representative
calcium supplements with the new method was performed.
The results showed that all products we tested can meet the USP guidelines in
physical properties and disintegration requirement. Product disintegration times wee
affected by pH effects, to some extent, with disintegration prolonged at more basic pH.
For dissolution, the current USP test is not sensitive for most calcium products. The
limitations of the regular USP test resulted in limited dissolution (i.e. under 30%),
which may be related to the poor solubility of calcium salts in the dissolution medium.
In order to develop a more sensitive testing method, different approaches to change
the dissolution parameters were experimented so that a best testing criterion was
eventually decided.
This revised testing methodology was based on the experiments of products in
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traditional tablet formulation. It was also then used in the test of some chewable
calcium tablets. The results confirmed that this revised method also improved the
sensitivity of USP dissolution test in chewable tablets.
The success of this revised test may not only be limited in the testing of calcium
supplement. In recent years the use of surfactant in the dissolution test, as in this
“optimized” method, has been included in more and more USP monograph. Similar
approaches can be used in a number of other products with less soluble active
ingredients.
For calcium supplements, more new formulations and new calcium salt forms
have emerged in the past few years. Most came to the market with a self-claim of
improved dissolution. Therefore more follow-up research in this field is needed to
characterize these products’ efficacy and satisfy the consumers’ ability to make the
right choice.
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